FUJIFILM Biosciences and NextCell Launch Commercial MSC Research Platform to Address Cell Therapy Development Challenges
核心洞察
FUJIFILM Biosciences (搜索) and NextCell Pharma AB have launched a new commercial mesenchymal stromal cell research platform combining PRIME-XV MSC Expansion XSFM (搜索) medium with NextCell-Cord RUO (搜索) umbilical cord-derived cells.
The platform addresses key MSC research challenges including cell heterogeneity, immunocompatibility issues, and inefficient manufacturing processes through standardized, high-quality solutions.
NextCell-Cord RUO (搜索) is available globally as a standalone product or bundled with FUJIFILM's media and reagents, supporting researchers in immunology, regenerative medicine, and cell therapy development.
FUJIFILM Biosciences (搜索) and NextCell Pharma AB have announced the global commercial launch of a new mesenchymal stromal cell (MSC) research platform designed to address persistent challenges in cell therapy development. The collaboration combines FUJIFILM Biosciences' PRIME-XV MSC Expansion XSFM (搜索) medium with NextCell's first commercial product, NextCell-Cord RUO (搜索), a research-use-only MSC product derived from umbilical cord tissue.
Addressing Critical MSC Research Challenges
The new platform specifically targets three major obstacles that have hindered MSC research progress: heterogeneity of MSCs, immunocompatibility issues, and inefficient manufacturing processes. NextCell-Cord RUO (搜索) provides researchers with a more consistent, efficient, and readily available source of umbilical cord-derived MSCs compared to traditional approaches.
"We've worked with FUJIFILM Biosciences (搜索) to ensure that this product meets the needs of researchers and drug developers who value consistency, scalability, and translational relevance," said Dr. Lindsay Davies, chief scientific officer at NextCell Pharma AB. "NextCell-Cord RUO (搜索) reflects not only our clinical manufacturing expertise, but also a commitment to delivering high-quality, standardized MSC products that are scientifically robust and immediately usable in research and development workflows."
Platform Components and Availability
The research platform pairs NextCell-Cord RUO (搜索) stromal cells with FUJIFILM Biosciences (搜索)' PRIME-XV MSC Expansion XSFM (搜索) medium, recombinant growth factors, and reagents to support robust MSC expansion and streamlined workflows. NextCell-Cord RUO cells are designed for delivery as cryopreserved products and are available across all major global markets through FUJIFILM Biosciences.
Researchers can purchase NextCell-Cord RUO (搜索) as a standalone product or as part of a bundled solution that includes FUJIFILM's media and reagent components. This flexibility allows laboratories to integrate the platform into existing workflows while maintaining standardization across experiments.
Strategic Collaboration Impact
The partnership represents a significant milestone for NextCell Pharma AB, marking the company's entry into the commercial market with its proprietary MSC platform. For FUJIFILM Biosciences (搜索), the collaboration expands its portfolio of life science solutions targeting immunology, regenerative medicine, and cell therapy development.
"FUJIFILM Biosciences (搜索) is committed to paving a better way forward with life science products, services, and solutions that serve the evolving needs of our academia, biotech, and pharmaceutical partners worldwide," said Brandon Pence, president and chief operations officer at FUJIFILM Biosciences. "Our strategic alliance with NextCell Pharma further strengthens our commitment to enabling our customers to achieve more with products and solutions they need every day to help create a healthier world for all."
"This product launch is a milestone for NextCell Pharma AB," added Mathias Svahn, chief executive officer of NextCell Pharma AB. "It brings our proprietary MSC platform to a global audience, and we are proud to do so in close collaboration with FUJIFILM Biosciences (搜索), a trusted leader in life science solutions."
The platform aims to provide laboratories worldwide with high-quality, standardized, and accessible solutions for advancing MSC research and supporting the development of next-generation cell therapies.